文献速递白血病

靶向SHMT1和SHMT2治疗T细胞急性淋巴细胞白血病

Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
PubMed 文献 · Leukemia · 2021-08-02

该研究通过全基因组CRISPR-Cas9筛选发现一碳叶酸通路是T-ALL增殖的关键代谢依赖,使用SHMT1/2抑制剂RZ-2994可诱导S/G2细胞周期阻滞并抑制白血病进展,且在甲氨蝶呤耐药背景下仍有效。

要点

  • 一碳叶酸、嘌呤和嘧啶通路是T-ALL增殖所需的主要代谢通路。
  • RZ-2994抑制SHMT1/2诱导T-ALL细胞S/G2周期阻滞,外源甲酸盐可挽救。
  • RZ-2994在体内降低白血病负荷,且对甲氨蝶呤耐药T-ALL仍有效。

核心结论

  • 一碳叶酸通路在T-ALL中具有重要地位,支持进一步开发SHMT抑制剂治疗T-ALL及其他癌症。

研究设计与样本

  • 采用无偏全基因组CRISPR-Cas9筛选鉴定T-ALL的通路依赖,并用SHMT1/2抑制剂RZ-2994在T-ALL细胞系及体内模型中验证。

主要发现

  • 一碳叶酸、嘌呤和嘧啶通路是T-ALL增殖所需的主要代谢通路。
  • T-ALL细胞系对RZ-2994敏感性存在差异,药物诱导S/G2细胞周期阻滞。
  • 甲酸盐补充可挽救SHMT1/2抑制的效应。
  • 同时缺失SHMT1和SHMT2才能导致生长受损和细胞周期阻滞,抑制两者可抑制体内白血病进展。
  • RZ-2994在体内降低白血病负荷,且在体外甲氨蝶呤耐药背景下仍有效。

临床怎么用

  • SHMT1/2抑制剂RZ-2994可能成为T-ALL(包括甲氨蝶呤耐药)的候选治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite progress in the treatment of acute lymphoblastic leukemia (ALL), T-cell ALL (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Using an unbiased genome-scale CRISPR-Cas9 screen we sought to identify pathway dependencies for T-ALL which could be harnessed for therapy development. Disruption of the one-carbon folate, purine and pyrimidine pathways scored as the top metabolic pathways required for T-ALL proliferation. We used a recently developed inhibitor of SHMT1 and SHMT2, RZ-2994, to characterize the effect of inhibiting these enzymes of the one-carbon folate pathway in T-ALL and found that T-ALL cell lines were differentially sensitive to RZ-2994, with the drug inducing a S/G2 cell cycle arrest. The effects of SHMT1/2 inhibition were rescued by formate supplementation. Loss of both SHMT1 and SHMT2 was necessary for impaired growth and cell cycle arrest, with suppression of both SHMT1 and SHMT2 inhibiting leukemia progression in vivo. RZ-2994 also decreased leukemia burden in vivo and remained effective in the setting of methotrexate resistance in vitro. This study highlights the significance of the one-carbon folate pathway in T-ALL and supports further development of SHMT inhibitors for treatment of T-ALL and other cancers.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pikman Y, Ocasio-Martinez N, Alexe G, et al. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia. 2021. PMID: 34341479. doi:10.1038/s41375-021-01361-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。